



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




CDKI-73

Item No. 41099

CAS Registry No.: 1421693-22-2
Formal Name: 3-[[5-fluoro-4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-benzenesulfonamide

Synonym: Asnuciclib
MF: C₁₅H₁₅FN₆O₂S₂
FW: 394.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CDKI-73 is supplied as a solid. A stock solution may be made by dissolving the CDKI-73 in the solvent of choice, which should be purged with an inert gas. CDKI-73 is sparingly soluble (1-10 mg/ml) in DMSO.

Description

CDKI-73 is an inhibitor of Cdk9/cyclin T1, Cdk1/cyclin B, and Cdk2/cyclin A complexes (K_i s = 4, 4, and 3 nM, respectively).¹ It is selective for these complexes over the Cdk7/cyclin H complex (K_i = 91 nM). CDKI-73 is cytotoxic to HCT116 colorectal cancer cells (GI_{50} = <10 nM). CDKI-73 (0.25 or 1 μ M) induces apoptosis in COLO 205, HCT116, HT-29, and KM12 colorectal cancer cells.² It reduces the levels of Bcl-2, cyclin D1, and myeloid cell leukemia-1 (Mcl-1), as well as decreases the mitochondrial membrane potential, in HCT116 cells when used at a concentration of 0.25 μ M. *In vivo*, CDKI-73 (100 mg/kg every three days) decreases tumor volume in an HCT116 mouse xenograft model to a greater extent than the DNA-crosslinking agent cisplatin (Item No. 13119).

References

1. Shao, H., Shi, S., Huang, S., *et al.* Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: Synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. *J. Med. Chem.* **56**(3), 640-659 (2013).
2. Rahaman, M.H., Lam, F., Zhong, L., *et al.* Targeting CDK9 for treatment of colorectal cancer. *Mol. Oncol.* **13**(10), 2178-2193 (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/25/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM